Zentek Ltd. · TSX-V: ZEN · Guelph, Ontario · August 2026
Three deep-science platforms - potential nuclear-grade graphite, graphene coatings, and aptamer biosciences - on a single client-funded, development-on-demand CRO model that owns the IP and minimises dilution.
Shareholder notice · Nasdaq listing
Nasdaq issued a delisting determination against Zentek on the US$1.00 minimum bid price requirement. Our common shares began trading in the United States on the OTCQX Best Market under the symbol ZTEKF on September 2, 2026. Here is what that changes, what it does not, and what, if anything, you need to do.
Last updated: September 2, 2026
Nasdaq requires a listed share to close at or above US$1.00. We did not meet that in either of the two compliance periods the rules allow, so Nasdaq issued a delisting determination. Our Nasdaq trading was suspended on September 2, 2026 and our shares are now quoted in the United States on the OTCQX Best Market under ZTEKF. Our TSX Venture listing, ZEN, is unaffected.
No. You own the same number of shares today that you owned yesterday. A listing is where a share trades. It is not what a share is.
Yes. Our shares trade on the TSX Venture Exchange under ZEN, and that listing is unaffected. It is our primary listing. In the United States our shares are quoted on the OTCQX Best Market under ZTEKF.
Nothing. Your broker trades ZEN on the TSX Venture Exchange the same way it always has.
Nothing. Nasdaq trading was suspended at the open on September 2, 2026, and our shares are now quoted in the United States on the OTCQX Best Market under the symbol ZTEKF. Your position carried across. If you search ZTEK and find nothing, that is why. You can also hold and trade the TSX Venture line, ZEN, through a broker with Canadian market access. Both lines are the same shares in the same company.
Companies whose primary listing is outside the United States are commonly given a five-letter symbol ending in F when they are quoted over the counter. The F indicates a foreign issuer. It is a naming convention, not a change to the shares.
No. You do not need to move your account, sell, re-register, or fill in a form. Most U.S. brokers support over-the-counter trading. Rules can vary by broker and by account type, so if you have questions about your own account, ask your broker directly.
A letter from Nasdaq saying a company no longer meets a listing rule and its shares are subject to removal from the exchange. It is a step in a process, not the end of one.
An independent panel inside Nasdaq that hears a company’s case. A company that receives a determination can request a hearing. We intend to request one.
No, and it did not. There is a specific Nasdaq rule that removes that protection where the company was in a second 180-day compliance period, which is where we were, so Nasdaq trading was suspended on September 2. Requesting a hearing does keep us registered with the U.S. Securities and Exchange Commission and does keep us filing there.
A U.S. market where shares trade through broker-dealers rather than on a stock exchange. Trades are real and prices are real, and the broker-dealers involved are regulated. It is less visible than Nasdaq: some brokerage screens, screening tools and data feeds cover it less well than they cover an exchange listing.
The OTC market has tiers. We are on OTCQX, the top one. We applied and paid for an expedited review, and the approval was in hand before the first day of quotation, so our shares went straight to OTCQX rather than sitting on a lower tier while the application processed.
Yes. OTCQX has its own standards for financial condition, disclosure and current information, and quotation there is not guaranteed indefinitely. We intend to meet them. If that ever changes, we will announce it.
At the open on Wednesday, September 2, 2026. Nasdaq trading was suspended the same morning.
We are not going to predict that, and you should be careful with anyone who does. Any step we take on the listing is something we have to disclose publicly, and you will read it from us on the day we take it.
Anything of that kind is a disclosure event, and where shareholder approval is required, it would be put to shareholders in a circular ahead of a meeting. We are not going to get ahead of that. If it is proposed, you will receive the full document, in advance, with time to read it and most importantly to vote.
No. The deposit, our ownership of it, the environmental and community work, and the PEA results we announced on August 10 are all unaffected.
No. Our customer buys filtration media. None of the commercial work is conditioned on which exchange our shares trade on.
No. That financing closed on May 27 for gross proceeds of C$18.0 million. Our cash position is reported in our quarterly financial statements, which are filed on SEDAR+ and EDGAR.
It means our share price did not meet a specific Nasdaq threshold. That is a share price fact. It is not a statement about the assets, the technology, the balance sheet or the work. We would rather you judged us on the record of what we have announced and delivered, which is published and which you can check.
If your broker shows nothing when you search ZTEK, search ZTEKF instead. Symbol changes can take a day or two to propagate through some platforms, and your position has not gone anywhere. Email us at info@zentek.com with the broker’s name and what the screen says. We are tracking this, and where a broker or a data provider has it wrong we go and get it fixed.
Our news releases, our filings on SEDAR+ and EDGAR, and this page. If you see something about Zentek anywhere else, check it here first.
Mohammed (Moe) Jiwan · mjiwan2@zentek.com · 437 826 3779
General enquiries: (844) 730-9822 · info@zentek.com
This page contains forward-looking information, including statements about our intention to request a hearing before a Nasdaq Hearings Panel and about continued quotation on the OTCQX Best Market. There is no assurance as to the outcome of the hearing process, that our shares will be relisted, that we will regain compliance with any Nasdaq listing requirement, or that we will continue to satisfy the requirements for trading on OTCQX. Trading over the counter in the United States may be less liquid than trading on a national securities exchange. See the risk factors in our filings on SEDAR+ and EDGAR. This page is not an offer to sell or a solicitation of an offer to buy any security, and it is not tax, legal or investment advice. Our filings govern.
Listing & capital structure
Zentek Ltd. is a reporting issuer in Canada and a foreign private issuer in the United States, filing on Form 6-K. All financial information is reported in Canadian dollars under IFRS.
Share prices are provided for information only, are delayed by at least 15 minutes, and may differ from the official exchange record. They are not a quotation on which any purchase or sale can be made and do not constitute investment advice.
| Common shares outstanding | 126,619,532 |
| Stock options (exercisable) | 5,311,750 |
| Restricted share units (RSUs) | 1,006,000 |
| Warrants outstanding | 22,461,060 |
| Shares issuable upon conversion of convertible debentures (at $2.20) | ~909,091 |
| Fully diluted shares | ~156,307,433 |
The numbers
Our three platforms are structurally independent: different markets, different buyers, different commercial triggers. Any one of them achieving commercial traction is a re-rating event. All three in motion simultaneously is the full thesis.
Investment strategy
We believe three structural conditions have converged simultaneously: geopolitical tailwinds, commercially-ready science, and a proven model.
Export licensing restrictions introduced in 2023 triggered over $1.8B in North American capacity announcements. Emerging pathogen threats have put significant US government biosecurity funding in play. Supply chain sovereignty is now a national security mandate across all Five Eyes nations: written into procurement frameworks, not just policy papers.
Thirty years of aptamer research is now commercially deployable for the first time. Triera has the team and the IP that makes that possible. Graphene coatings are moving from laboratory to industrial scale. Albany graphite has demonstrated bench-scale purity results consistent with published nuclear-grade thresholds, through independent testing. These are not projections: they are published, peer-reviewed, independently verified results.
The client-funded CRO model - industry brings the problem, Zentek develops the solution and owns the IP - has created multi-billion dollar companies in pharma (Charles River, ICON) and specialty materials (NanoXplore, Aptamer Group). Non-dilutive government funding can potentially offset R&D costs. No manufacturing capex required.
Filings & documents
Corporate presentation, quarterly and annual filings, and regulatory reports. All continuous disclosure documents are also available on SEDAR+ and EDGAR.
The current investor deck covering the three platforms, the client-funded CRO model, and the valuation thesis. View it in the browser or download the presentation.
Investor relations
Zentek is actively seeking strategic partners and long-term investors who recognise the convergence of critical minerals supply chain urgency, advanced air quality requirements, and next-generation therapeutic development. If you are exploring any of these areas, we would like to hear from you.
For investor enquiries, meeting requests, and continuous disclosure questions. Toll-free (844) 730-9822.
ir@zentek.comStrategic partnerships · licensing · co-development opportunities. Toll-free (844) 730-9822.
info@zentek.comInteractive tools · explore the data
Three interactive tools built to help investors, analysts, and technical partners understand the Albany deposit, its economics, and the global graphite market context.
An animated walkthrough of the global graphite supply chain - from mine to reactor - and where Albany sits within it. Built for investor conversations and partner briefings.
Adjust cut-off grade, recovery rates, and market pricing to model Albany's economics in real time. Understand the sensitivity of the project to key variables.
A plain-language explainer covering graphite grades, crystalline structure, processing requirements, and why Albany's igneous-hosted, fluid-derived origin matters for downstream applications.
Forward-looking information
This page contains forward-looking information within the meaning of applicable Canadian and United States securities laws, including statements about market opportunities, development timelines, potential revenue, valuation multiples, and funding sources. Forward-looking statements involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied. Zentek Ltd. (TSX-V: ZEN) is a reporting issuer in Canada and a foreign private issuer in the United States, filing financial reports on Form 6-K under IFRS in Canadian dollars.
Nothing on this page constitutes a mineral resource or reserve estimate under NI 43-101, a medical claim, financial advice, or an offer or solicitation to buy or sell securities. Readers are referred to Zentek's continuous disclosure documents on SEDAR+ and EDGAR for complete risk factor disclosure. Full legal disclaimers →